Systemic autoimmune disease

Systemic autoimmune disease (Orphanet code 182228) is a broad classification category encompassing a group of rare and complex disorders in which the immune system mistakenly attacks the body's own tissues and organs in a widespread, systemic manner. Unlike organ-specific autoimmune conditions, systemic autoimmune diseases can affect multiple body systems simultaneously, including the joints, skin, kidneys, blood cells, heart, lungs, and nervous system. Well-known examples falling under this umbrella include systemic lupus erythematosus (SLE), systemic sclerosis (scleroderma), Sjögren syndrome, and mixed connective tissue disease, among others. Key clinical features vary depending on the specific condition but commonly include chronic fatigue, joint pain and swelling, skin rashes, fever, and inflammation affecting internal organs. Patients may experience periods of disease flares alternating with remissions. Serious complications can include kidney failure (lupus nephritis), pulmonary fibrosis, vasculitis, and increased cardiovascular risk. Laboratory findings often include the presence of autoantibodies (such as antinuclear antibodies), elevated inflammatory markers, and cytopenias. Treatment approaches are tailored to the specific diagnosis and severity of organ involvement. Common therapeutic strategies include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, conventional immunosuppressants (such as methotrexate, azathioprine, and mycophenolate mofetil), and targeted biologic therapies (such as belimumab for SLE or rituximab). Management typically requires a multidisciplinary team including rheumatologists, nephrologists, dermatologists, and other specialists. Early diagnosis and ongoing monitoring are essential to prevent irreversible organ damage and improve long-term outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Systemic autoimmune disease